Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors

#313

Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).

Aim(s): Evaluation of disease control rate and progression-free survival (PFS) of metastatic LCT patients treated with long-acting Somatostatin analogues alone.

Materials and methods: Eighteen out of 39 metastatic LCT patients followed between 2000 and 2009, were treated with somatostatin analogues alone and were retrospectively reviewed. Response rates were evaluated according to RECIST criteria. Mean PFS was estimated by the Kaplan-Meier method and compared between groups (typical or atypical CT) using the Log-Rank test.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Fekih M, Baudin E, Ducreux M, Chougnet C, Leboulleux S,

Keywords: carcinoid tumor, neuroendocrine tumors, therapeutics, Somatostatin analogues, lung,